Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Ancestry-based pharmacogenomics, adverse reactions and carbamazepine: is the FDA warning correct?

The pharmacogenomics journal - 1 Oct 2014

Payne P W

Abstract excerpt

In an effort to prevent potentially fatal adverse reactions to carbamazepine, the US Food and Drug Administration (FDA) issued an alert in 2007 containing pharmacogenomic information, which is still in effect today. The alert states that carbamazepine-induced skin reactions are significantly more common in patients with the human leukocyte antigen (HLA)-B*1502 allele and that these people are almost exclusively...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anticonvulsants
Share to Asian People
Share to Carbamazepine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HLA-B15 Antigen

Share to Pharmacogenetics

Share to Reproducibility of Results

Share to United States

Share to United States Food and Drug Administration

Source

Identifiers

PMID: 24752310
DOI: 10.1038/tpj.2014.14

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Ancestry-based pharmacogenomics, adverse reactions and carbamazepine: is the FDA warning correct?PMID 24752310Read ↗

HLA-B Genotyping to Detect Carbamazepine-Induced Stevens-Johnson Syndrome: Implications for Personalizing MedicineSemantic proximity Read ↗

Carbamazepine, HLA-B*1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations.Semantic proximity Read ↗

Tailoring of recommendations to reduce serious cutaneous adverse drug reactions: a pharmacogenomics approach.Semantic proximity Read ↗

HLA genotype and carbamazepine-induced cutaneous adverse drug reactions: a systematic review.Semantic proximity Read ↗

HLA genotype testing for carbamazepine, oxcarbazepine and eslicarbazepine: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI-PGx).Semantic proximity Read ↗

Clinical application of pharmacogenomics: the example of HLA-based drug-induced toxicity.Semantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 UpdateSemantic proximity Read ↗

Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions.Semantic proximity Read ↗

Associations of HLA genetic variants with carbamazepine-induced cutaneous adverse drug reactions: An updated meta-analysis.Semantic proximity Read ↗

A Recent Update of Pharmacogenomics in Drug-induced Severe Skin ReactionsSemantic proximity Read ↗

HLA alleles and hypersensitivity to carbamazepine: an updated systematic review with meta-analysis.Semantic proximity Read ↗

The pharmacogenomics of epilepsySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.